Key Points
- Insider Johanna Mercier sold 3,000 Gilead shares on April 15 for about $422,880 — the trade was executed under a pre‑arranged Rule 10b5‑1 plan and follows prior sales in March and February, leaving her with 128,779 shares (≈$18.15M), a 2.28% ownership reduction.
- Earnings and outlook: Gilead slightly beat quarterly estimates (EPS $1.86 vs. $1.83; revenue $7.93B vs. $7.68B), set FY2026 guidance of $8.45–$8.85 EPS, raised its quarterly dividend to $0.82 (annual $3.28, ~2.4% yield), and carries a consensus analyst rating of Moderate Buy with a $156.77 target.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider directly owned 128,779 shares of the company's stock, valued at approximately $18,152,687.84. This trade represents a 2.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Johanna Mercier also recently made the following trade(s):
- On Monday, March 16th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $144.23, for a total value of $432,690.00.
- On Tuesday, February 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00.
Gilead Sciences Price Performance
Gilead Sciences stock opened at $138.55 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $171.97 billion, a P/E ratio of 20.47, a PEG ratio of 1.86 and a beta of 0.39. The business has a 50-day moving average of $144.65 and a 200-day moving average of $131.10. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences's quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a $0.82 dividend. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences's dividend payout ratio (DPR) is presently 48.45%.
Analyst Upgrades and Downgrades
GILD has been the subject of a number of research analyst reports. Scotiabank boosted their target price on Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a research note on Wednesday, February 11th. Truist Financial lifted their price objective on Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a report on Wednesday, February 11th. The Goldman Sachs Group increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock a "neutral" rating in a research note on Thursday, January 8th. Rothschild & Co Redburn raised their target price on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Finally, Wolfe Research lifted their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an "outperform" rating in a research note on Thursday, February 12th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $156.77.
View Our Latest Report on Gilead Sciences
Institutional Investors Weigh In On Gilead Sciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences during the third quarter valued at approximately $26,000. Quattro Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $26,000. Finally, Wealth Preservation Advisors LLC grew its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. 83.67% of the stock is owned by institutional investors.
Key Headlines Impacting Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
